Remote digital cognitive assessment reveals cognitive deficits related to hippocampal atrophy in autoimmune limbic encephalitis: a cross-sectional validation study

Autoimmune Limbic Encephalitis (ALE) is a neurological disease characterised by inflammation of the limbic regions of the brain, mediated by pathogenic autoantibodies. Because cognitive deficits persist following acute treatment of ALE, the accurate assessment of long-term cognitive outcomes is important for clinical assessments and trials. However, evaluating cognition is costly and an unmet need for validated digital methods exists. We investigated whether remote digital methods could identify previously characterised cognitive impairments in ALE patients and would correlate with standard neuropsychological assessment and hippocampal volume. The cognitive performance of 21 chronic ALE patients along with 54 age-matched healthy controls was assessed with a battery of 12 cognitive tasks from the Cognitron online platform. ALE patients performed significantly worse in memory, visuospatial abilities, executive function, and language. No impairments in digit & spatial span, target detection (attention) and emotion discrimination were observed. The global score on the online cognitive tasks correlated significantly with the established Addenbrooke's Cognitive Examination III (ACE) pen-and-paper test. Deficits in visuospatial processing and language were identified in ALE compared to controls using remote digital testing but not the ACE, highlighting higher sensitivity of computerised testing to residual cognitive impairment. Finally, the hippocampal volume of ALE patients and healthy controls correlated with online cognitive scores. Overall, these findings demonstrate that remote, online testing may facilitate the characterisation of cognitive profiles in complex neurological diseases.

[1]  Peter J Hellyer,et al.  Computerised cognitive assessment in patients with traumatic brain injury: an observational study of feasibility and sensitivity relative to established clinical scales , 2023, EClinicalMedicine.

[2]  D. Perani,et al.  Review and meta-analysis of neuropsychological findings in autoimmune limbic encephalitis with autoantibodies against LGI1, CASPR2, and GAD65 and their response to immunotherapy , 2022, Clinical Neurology and Neurosurgery.

[3]  C. Arias,et al.  1543. Validation of a Nitrocefin-based Rapid Test for the Detection of the Cefazolin Inoculum Effect in Pediatric Patients with Methicillin-Susceptible Staphylococcus aureus Acute Osteomyelitis , 2022, Open Forum Infectious Diseases.

[4]  J. Lace,et al.  Cognitive outcomes in anti-LGI-1 encephalitis , 2022, Journal of the International Neuropsychological Society.

[5]  T. Lee,et al.  Digital Cognitive Biomarker for Mild Cognitive Impairments and Dementia: A Systematic Review , 2022, Journal of clinical medicine.

[6]  Peter J Hellyer,et al.  Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort , 2022, eClinicalMedicine.

[7]  M. Rosenfeld,et al.  Human CASPR2 Antibodies Reversibly Alter Memory and the CASPR2 Protein Complex , 2022, Annals of neurology.

[8]  T. Goldberg,et al.  Validity of the Web-Based, Self-Directed, NeuroCognitive Performance Test in Mild Cognitive Impairment. , 2022, Journal of Alzheimer's disease : JAD.

[9]  J. Britton,et al.  LGI1 antibody encephalitis: acute treatment comparisons and outcome , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  Peter J Hellyer,et al.  Rapid vigilance and episodic memory decrements in COVID-19 survivors , 2021, medRxiv.

[11]  M. Husain,et al.  Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis , 2021, JAMA neurology.

[12]  K. Papp,et al.  Current advances in digital cognitive assessment for preclinical Alzheimer's disease , 2021, Alzheimer's & dementia.

[13]  Peter J Hellyer,et al.  Cognitive deficits in people who have recovered from COVID-19 , 2020, EClinicalMedicine.

[14]  J. Molinuevo,et al.  FLAME: A computerized neuropsychological composite for trials in early dementia , 2020, Alzheimer's & dementia.

[15]  Jingping Shi,et al.  Clinical Characteristics of Cognitive Impairment and 1-Year Outcome in Patients With Anti-LGI1 Antibody Encephalitis , 2020, Frontiers in Neurology.

[16]  C. Malpas,et al.  The neuropsychological spectrum of anti-LGI1 antibody mediated autoimmune encephalitis , 2020, Journal of Neuroimmunology.

[17]  Arjune Sen,et al.  Distinctive binding properties of human monoclonal LGI1 autoantibodies determine pathogenic mechanisms , 2020, Brain : a journal of neurology.

[18]  J. Routy,et al.  Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation , 2019, Medicine.

[19]  J. Born,et al.  Hippocampal Dentate Gyrus Atrophy Predicts Pattern Separation Impairment in Patients with LGI1 Encephalitis , 2019, Neuroscience.

[20]  Adam G. Thomas,et al.  Hippocampal Functional Dynamics Are Clinically Implicated in Autoimmune Encephalitis With Faciobrachial Dystonic Seizures , 2018, Front. Neurol..

[21]  F. Paul,et al.  Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[22]  G. Widman,et al.  The importance of early immunotherapy in patients with faciobrachial dystonic seizures , 2017, Brain : a journal of neurology.

[23]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[24]  J. Britton,et al.  Expanded phenotypes and outcomes among 256 LGI1/CASPR2‐IgG–positive patients , 2017, Annals of neurology.

[25]  Ludovica Griffanti,et al.  Image processing and Quality Control for the first 10,000 brain imaging datasets from UK Biobank , 2017, NeuroImage.

[26]  Michael R. Johnson,et al.  Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis , 2017, Brain : a journal of neurology.

[27]  R. Stenton,et al.  Utility, reliability, sensitivity and validity of an online test system designed to monitor changes in cognitive function in clinical trials , 2017, International journal of geriatric psychiatry.

[28]  D. Perani,et al.  Neuropsychological and FDG-PET profiles in VGKC autoimmune limbic encephalitis , 2016, Brain and Cognition.

[29]  Yadin Dudai,et al.  The Consolidation and Transformation of Memory , 2015, Neuron.

[30]  Andrew Simmons,et al.  The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease , 2014, Front. Aging Neurosci..

[31]  J. Neuhaus,et al.  More than memory impairment in voltage‐gated potassium channel complex encephalopathy , 2014, European journal of neurology.

[32]  John R Clark,et al.  When good isn't good enough. , 2014, Air medical journal.

[33]  M. Jorge Cardoso,et al.  Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype , 2013 .

[34]  C. Elger,et al.  Neuropsychological course of voltage‐gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis , 2013, European journal of neurology.

[35]  John R. Hodges,et al.  Validation of the Addenbrooke's Cognitive Examination III in Frontotemporal Dementia and Alzheimer's Disease , 2013, Dementia and Geriatric Cognitive Disorders.

[36]  Jonathan M. Schott,et al.  Binding deficits in memory following medial temporal lobe damage in patients with voltage-gated potassium channel complex antibody-associated limbic encephalitis , 2013, Brain : a journal of neurology.

[37]  L. Honig,et al.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study , 2013, The Lancet Neurology.

[38]  C. Goujard,et al.  Treatment of limbic encephalitis with anti-glioma-inactivated 1 (LGI1) antibodies , 2012, Journal of Clinical Neuroscience.

[39]  K. Jellinger,et al.  Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. , 2012, Brain : a journal of neurology.

[40]  J. Schott,et al.  Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis , 2011, Annals of neurology.

[41]  C. Elger,et al.  Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy , 2007, Neurology.

[42]  G. Handelmann,et al.  Hippocampus, space, and memory , 1979 .

[43]  G. Day Rethinking Outcomes in Leucine-Rich, Glioma-Inactivated 1 Protein Encephalitis: "Good" Isn't Good Enough. , 2017, JAMA neurology.

[44]  G. Deuschl,et al.  Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies , 2017, JAMA neurology.

[45]  A. Vincent,et al.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia , 2010, Brain : a journal of neurology.

[46]  R. Morris,et al.  Hippocampal-neocortical interactions in memory formation, consolidation, and reconsolidation. , 2010, Annual review of psychology.